Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of Schizophrenia

Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of... References1. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psycho-pharmacology. J Psychopharmacol 2011; 25(5):567–620. https://doi.org/10.1177/02698811103911232. Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psycho-pharmacol 2014;4(5):198-219. https://doi.org/10.1177/20451253145402973. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16(2):231–9. https://doi.org/10.3111/13696998.2012.7510254. Bera R, Offord S, Zubek D, et al. Impact on health-care resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013;16(4):522–8. https://doi.org/10.3111/13696998.2013.7716415. Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes 2012;10:35. https://doi.org/10.1186/1477-7525-10-356. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(5):15–18.7. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation anti-psychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010;24(10):1473–82. https://doi.org/10.1177/02698811091048828. Potkin S, Bera R, ZubekD,Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013;13:261. https://doi.org/10.1186/1471-244X-13-2619. Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, Chue P, Malla A. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives. Can J Psychiatry 2013;14:22. https://doi.org/10.1177/088740341305805s0310. Cocoman A, Murray J. Intramuscular injections: a review of best practice for mental health nurses. J PsychiatrMent Health Nurs 2008;15:424–34. https://doi.org/10.1111/j.1365-2850.2007.01236.x11. Wynaden D, Landsborough I, McGowan S, Baigmohamad Z, Finn M, Pennebaker D, et al. Best practice guidelines for the administration of intramuscular injections in the mental health setting. Int J Ment Health Nurs 2006;15:195–200. https://doi.org/10.1111/j.1447-0349.2006.00423.x12. Gray R, Spilling R, Burgess D, Newey T. Anti-psychotic long acting injections in clinical practice: medication management and patient choice. Br J Psychiatry 2009; 18 (25): 51-6. https://doi.org/10.1192/bjp.195.52.s5113. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010;175:58–62. https://doi.org/10.1016/j.psychres.2008.11.00314. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatry Pract 2010;16(5):306-24. https://doi.org/10.1097/01.pra.0000388626.98662.a015. Windell D, Norman R. A qualitative analysis of influences on recovery following a first episode of psychosis. Int J Soc Psychiatry 2013;59:493–500. https://doi.org/10.1177/002076401244375116. Acosta FJ, Chinea E, Hernández JL, Rodríguez F, García-Bello M, Medina G, Nieves W. Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia. Nord J Psychiatry 2014;68(3):180-8 https://doi.org/10.3109/08039488.2013.790475 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Facultatis Medicae Naissensis de Gruyter

Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of Schizophrenia

Loading next page...
 
/lp/de-gruyter/problems-with-the-administration-of-antipsychotic-drugs-in-depot-ybtODzi0m5
Publisher
de Gruyter
Copyright
© 2018 Anica Ranković et al., published by De Gruyter Open
ISSN
2217-2521
eISSN
2217-2521
DOI
10.2478/afmnai-2018-0007
Publisher site
See Article on Publisher Site

Abstract

References1. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psycho-pharmacology. J Psychopharmacol 2011; 25(5):567–620. https://doi.org/10.1177/02698811103911232. Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psycho-pharmacol 2014;4(5):198-219. https://doi.org/10.1177/20451253145402973. Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013;16(2):231–9. https://doi.org/10.3111/13696998.2012.7510254. Bera R, Offord S, Zubek D, et al. Impact on health-care resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013;16(4):522–8. https://doi.org/10.3111/13696998.2013.7716415. Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes 2012;10:35. https://doi.org/10.1186/1477-7525-10-356. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry 2006;67(5):15–18.7. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation anti-psychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010;24(10):1473–82. https://doi.org/10.1177/02698811091048828. Potkin S, Bera R, ZubekD,Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013;13:261. https://doi.org/10.1186/1471-244X-13-2619. Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, Chue P, Malla A. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives. Can J Psychiatry 2013;14:22. https://doi.org/10.1177/088740341305805s0310. Cocoman A, Murray J. Intramuscular injections: a review of best practice for mental health nurses. J PsychiatrMent Health Nurs 2008;15:424–34. https://doi.org/10.1111/j.1365-2850.2007.01236.x11. Wynaden D, Landsborough I, McGowan S, Baigmohamad Z, Finn M, Pennebaker D, et al. Best practice guidelines for the administration of intramuscular injections in the mental health setting. Int J Ment Health Nurs 2006;15:195–200. https://doi.org/10.1111/j.1447-0349.2006.00423.x12. Gray R, Spilling R, Burgess D, Newey T. Anti-psychotic long acting injections in clinical practice: medication management and patient choice. Br J Psychiatry 2009; 18 (25): 51-6. https://doi.org/10.1192/bjp.195.52.s5113. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010;175:58–62. https://doi.org/10.1016/j.psychres.2008.11.00314. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatry Pract 2010;16(5):306-24. https://doi.org/10.1097/01.pra.0000388626.98662.a015. Windell D, Norman R. A qualitative analysis of influences on recovery following a first episode of psychosis. Int J Soc Psychiatry 2013;59:493–500. https://doi.org/10.1177/002076401244375116. Acosta FJ, Chinea E, Hernández JL, Rodríguez F, García-Bello M, Medina G, Nieves W. Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia. Nord J Psychiatry 2014;68(3):180-8 https://doi.org/10.3109/08039488.2013.790475

Journal

Acta Facultatis Medicae Naissensisde Gruyter

Published: Mar 1, 2018

There are no references for this article.